Abstract 1516P
Background
In the phase III KEYNOTE-859 study (NCT03675737), 1L pembro + chemo significantly improved OS, PFS, and ORR vs placebo (pbo) + chemo regardless of PD-L1 expression and had a manageable AE profile in patients (pts) with locally advanced/metastatic HER2-negative G/GEJ adenocarcinoma. Prespecified exploratory HRQoL outcomes are reported.
Methods
HRQoL was assessed in treated pts who completed ≥1 HRQoL assessment using the EORTC QLQ-C30, EORTC QLQ-STO22, and EQ-5D-5L questionnaires. Least squares mean (LSM) changes from baseline (BL) to wk 18 in QLQ-C30 GHS/QoL; physical functioning (PF) and role functioning (RF) subscales; nausea/vomiting and appetite loss symptoms scales; QLQ-STO22 pain symptom scale; and EQ-5D-5L VAS were compared using a constrained longitudinal data analysis model (covariates: Tx by study visit interaction and stratification factors). Time to deterioration (TTD; ≥10-point decline from BL in a given scale/subscale) was estimated using the Kaplan-Meier method; between-arm difference (HR) was determined using a stratified Cox proportional hazards model.
Results
The latest timepoint at which the predefined rates of completion (≥60%) and compliance (≥80%) were met was wk 18. From BL to wk 18, LSM changes in QLQ-C30 GHS/QoL, PF, RF, nausea/vomiting, and appetite loss and EQ-5D-5L VAS were similar between arms; the QLQ-STO22 pain scale favored pembro + chemo (Table). TTD (HR; 95% CI) in QLQ-C30 GHS/QoL (0.87; 0.72-1.04), PF (0.91; 0.76-1.08), RF (0.90; 0.76-1.06), appetite loss (1.00; 0.82-1.22), and nausea/vomiting (0.95; 0.79-1.14) were similar between arms; the QLQ-STO22 pain scale favored pembro + chemo (0.76; 0.58-0.98).
Table: 1516P
Change from BL to wk 18, LSM (95% CI) | Difference in LSM change from BL to wk 18 (95% CI) | ||
Pembro + chemo | Pbo + chemo | ||
EORTC QLQ-C30 | n = 771 | n = 771 | N/A |
GHS/QoL | 0.40 (-1.37 to 2.18) | -0.85 (-2.62 to 0.93) | 1.25 (-1.07 to 3.58) |
PF | -5.87 (-7.53 to -4.22) | -7.53 (-9.18 to -5.88) | 1.65 (-0.64 to 3.94) |
RF | -5.41 (-7.59 to -3.22) | -7.97 (-10.15 to -5.79) | 2.57 (-0.38 to 5.52) |
Nausea/vomiting | 1.06 (-0.75 to 2.87) | 1.36 (-0.45 to 3.16) | -0.30 (-2.67 to 2.07) |
Appetite loss | -3.43 (-6.10 to -0.76) | -4.85 (-7.51 to -2.19) | 1.42 (-1.93 to 4.77) |
EORTC QLQ-STO22 pain | n = 754 -8.21 (-9.91 to -6.51) | n = 752 -5.64 (-7.34 to -3.94) | -2.57 (-4.72 to -0.41) |
EQ-5D-5L VAS | n = 771 -0.69 (-2.12 to 0.73) | n = 771 -1.91 (-3.33 to -0.49) | 1.22 (-0.65 to 3.08) |
Conclusions
HRQoL data from KEYNOTE-859, combined with efficacy and safety results, support a favorable benefit-to-risk profile for pembro + chemo as a new 1L Tx option for advanced HER2-negative G/GEJ adenocarcinoma.
Clinical trial identification
NCT03675737.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Obinna Ezeokoli, PhD, and Lauren D’Angelo, PhD, of ApotheCom (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The authors thank Yanfen Guan (of Merck & Co.,Inc., Rahway, NJ, USA) for their assistance with this analysis.
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
M.A. Lowery: Financial Interests, Personal, Invited Speaker, Educational session for trainees: Novartis; Financial Interests, Institutional, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Advisory Board: Agios, Servier; Financial Interests, Institutional, Other, Educational Grant: Roche; Financial Interests, Institutional, Research Grant: Genuity Science; Non-Financial Interests, Principal Investigator: MSD, Basilea, Exelixis, Astellas; Non-Financial Interests, Principal Investigator, Clinical trial: Daiichi Sankyo, Zymeworks. L.S. Wyrwicz: Financial Interests, Personal, Advisory Board: BMS, Servier; Financial Interests, Personal and Institutional, Local PI: BMS, MSD, Servier, BeiGene, Roche, AstraZeneca; Financial Interests, Personal, Steering Committee Member: AstraZeneca. D. Oh: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Genentech/Roche, Merck, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD; Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, Handok. K. Shiu: Financial Interests, Personal, Invited Speaker, Educational Webinars on CRC and UGI cancer management with immunotherapy: BMS; Financial Interests, Personal, Advisory Board, Advisory Board on Regorafenib for chemorefractory mCRC in readiness for NICE application: Bayer; Financial Interests, Personal, Invited Speaker, Educational webinars on Pembrolizumab for MSI-High CRC, as well as OG cancers: MSD; Financial Interests, Personal, Advisory Board, For Pembrolizumab in CRC of OG cancers pre or NICE application or post NICE approval: MSD; Financial Interests, Personal, Invited Speaker, Webinars on updates on management of mCRC: Merck; Financial Interests, Personal, Advisory Board, On Mirati GI Global Advisory Board: Mirati Therapeutics; Financial Interests, Personal, Invited Speaker, To update company on indications/updates in landscape of immunotherapy and vaccines in GI cancers: Nouscom; Financial Interests, Personal, Advisory Board, Advisory on Cancer of Unknown Primary, new indications of molecular profiling usingFoundation Medicine 1: Roche; Financial Interests, Personal, Advisory Board, Advisory Board on Lonsurf for chemorefractory mCRC in readiness for NICE application: Servier; Financial Interests, Institutional, Local PI, For MATTERHORN Trial: AstraZeneca; Financial Interests, Institutional, Coordinating PI, UK Chief Investigator on KEYNOTE 177, KEYNOTE 859, KEYNOTE 811, LEAP 17, MK1308A-008 trials: MSD; Financial Interests, Institutional, Research Grant, Chief Investigator of investigator initiated, MSD funded NEOPRISM-CRC trial: MSD; Financial Interests, Institutional, Local PI, UCLH PI for LEAP 15 and MK4280A-007 trials: MSD; Financial Interests, Institutional, Coordinating PI, UK Chief Investigator for NOUS209-001 trial: Nouscom; Financial Interests, Institutional, Coordinating PI, UK Chief Investigator for CUPSICO trial: Roche; Financial Interests, Personal, Steering Committee Member, Steering Committee Member of CUPISCO trial: Roche; Non-Financial Interests, Member: ASCO, Association of Cancer Physicians UK. F. Rivera: Financial Interests, Personal and Institutional, Invited Speaker: MSD, Lilly, Astellas, BMS, Roche, Amgen, Merck, Servier, Novartis; Financial Interests, Personal and Institutional, Advisory Board: MSD, Lilly, Astellas, BMS, Roche, Amgen, Merck, Servier; Financial Interests, Personal and Institutional, Research Grant: MSD, AstraZeneca, BMS, Amgen, Merck, Servier, Novartis; Financial Interests, Personal and Institutional, Funding: MSD, AstraZeneca, BMS, Roche, Amgen, Merck, Servier, Novartis; Financial Interests, Personal and Institutional, Principal Investigator: MSD, AstraZeneca, Amgen, Servier. G.V. Alves: Financial Interests, Personal, Invited Speaker, Speaker: Sanofi, AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory: AstraZeneca, Merck Serono, MSD; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Institutional, Local PI: MSD, BMS, AstraZeneca, Roche, BeiGene, Janssen, Aveo, Sanofi; Financial Interests, Institutional, Other, Sub-Investigator: Zymeworks. M. Garrido: Financial Interests, Personal, Invited Speaker: BMS, Novartis, Bayer, Pfizer, Merck, Lilly, GBT Biotoscana; Financial Interests, Personal, Advisory Board: MSD, Pfizer, MacroGenics; Financial Interests, Institutional, Invited Speaker: Merck; Financial Interests, Institutional, Research Grant: BMS, Novartis. J. Li: Non-Financial Interests, Member: ASCO, CSCO. F.J.S.M. Cruz: Non-Financial Interests, Institutional, Principal Investigator: AstraZeneca, MSD. L. Yin, A. Valderrama, S. Bordia: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. S.Y. Rha: Financial Interests, Personal, Advisory Board: Indivumed, Amgen, LG biochemical, Astellas; Financial Interests, Personal, Invited Speaker: MSD, Lilly, Daiichi Sankyo; Financial Interests, Personal, Steering Committee Member: Amgen; Financial Interests, Institutional, Funding: MSD, Lilly; Financial Interests, Institutional, Research Grant: BMS, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Indivumed, AstraZeneca; Financial Interests, Other, Drug supply for clinical trial: Merck; Financial Interests, Institutional, Coordinating PI, Drug supply for clinical trial: MSD; Financial Interests, Institutional, Local PI, drug supply for clinical trial: Zymeworks; Financial Interests, Institutional, Local PI, drug supply for clinical trial: BeiGene; Financial Interests, Coordinating PI, Drug supply for clinical trial: Incyte. All other authors have declared no conflicts of interest.
Resources from the same session
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21